StreetAlpha.app
Home › Stocks › EWTX

Edgewise Therapeutics, Inc. (EWTX)

Healthcare
$42.04
▼ −3.75%
LAST CLOSE · NOV 17

Edgewise Therapeutics develops small molecule medicines for rare muscle diseases, based in Boulder, Colorado. It last closed at $42.04 on Nov 17, down 3.75% on the day. The average 12-month price target from 3 analysts is $56.00 (+33.2% from the last close), with a high of $60.00 and a low of $51.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in EWTX, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is EWTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
$1.0B
EPS (diluted)
$8.38
Free cash flow
−$202.3M
Valuation
Market cap
$4.6B
109.5M shares
P/E
5.0
Price over 12 month EPS
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$68.7M
At Sep 30
Shareholder equity
$1.6B
Shares outstanding
109.5M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$42.8M−$42.8MFY2021FY2022: −$67.6M−$67.6MFY2022FY2023: −$100.2M−$100.2MFY2023FY2024: −$133.8M−$133.8MFY2024FY2025: −$167.8M−$167.8MFY2025

From EWTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on EWTX in the past 90 days
Average 12-month target
$56.00
▲ 33.2% upside

Based on 3 analysts who set a price target on EWTX in the past 90 days. The average target is $56.00, with a high of $60.00 and a low of $51.00, compared with the last close of $42.04.

Low $51.00Avg $56.00High $60.00
Blue marker: last close $42.04
Highest target$60.00
Average target$56.00
Lowest target$51.00
Latest rating changes
WedbushTarget lowered
Nov 5Buy$52 → $51
HC Wainwright & Co.Target raised
Sep 21Buy$45 → $57
JP MorganMaintained
Aug 20Buy$60
Goldman SachsTarget raised
Aug 11Hold$32 → $36
Evercore ISI GroupMaintained
Jul 20Buy$55
DateFirmActionRatingPrice target
Nov 5WedbushTarget loweredBuy$52 → $51
Sep 21HC Wainwright & Co.Target raisedBuy$45 → $57
Aug 20JP MorganMaintainedBuy$60
Aug 11Goldman SachsTarget raisedHold$32 → $36
Jul 20Evercore ISI GroupMaintainedBuy$55
Loading…

Technical Analysis

EWTX · as of the Nov 17 close · updated after every close
Uptrend

The stock is 1% above its 20 day and 2% above its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 50). The nearest support is the swing low (Aug 14) at $41.98, and the nearest resistance the swing high (Sep 30) at $42.12.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 6.6%/day
Key levels
$48.7852 week high+16.0%
$43.52Pivot R1+3.5%
$42.47Pivot+1.0%
$42.12Swing high (Sep 30)+0.2%
$42.04Last close
$41.98Swing low (Aug 14)−0.1%
$41.80100 day average−0.6%
$41.6720 day average−0.9%
$41.3150 day average−1.7%
$41.00Pivot S1−2.5%
$37.15200 day average−11.6%
$19.7652 week low−53.0%
Indicators
RSI (14)49.95Middle of its rangeNeutral
MACD1.30Above its signal lineBullish
Stochastic59.5Middle of its rangeNeutral
ADX (14)21.4Weak trend
Williams %R-55.8Oversold below −80, overbought above −20Neutral
CCI (20)18.9Oversold below −100, overbought above 100Neutral
Rate of change+11.6%Change over 10 sessionsBullish
ATR (14)$2.77Typical daily range, 6.6% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for EWTX

What happened before

See how EWTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow EWTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How EWTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
2
100%
Bearish
0
0%
Date span
Sep 16 – Sep 16
Loading…

See today’s whale options flow across the market →

EWTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲145 buying vs 92 selling
  • ▲Held by funds +5.3 pts
  • ▲Funds holding +27
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding253226+11.9%
In funds' top 101513+15.4%
Held by funds114.2%108.9%+5.3 pts
New / increased46 / 9940 / 83+17.9%
Reduced / sold out71 / 2172 / 26−6.1%
Put/call ratio0.870.49+77.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EWTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EWTX is in one of them and how their past EWTX trades turned out.

EWTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EWTX in an article yet. Here's the latest on the wider market.

About Edgewise Therapeutics

Edgewise Therapeutics is a biopharmaceutical company based in Boulder, Colorado, that develops small molecule medicines for serious muscle diseases. Its main candidates target rare muscular dystrophies, including Duchenne and Becker, and a heart condition called hypertrophic cardiomyopathy. The company uses its own drug discovery platform to find treatments that act on muscle tissue, and these candidates are still in clinical trials. It is developing the therapies for patients with these conditions and the physicians who treat them.

Headquarters
Boulder, CO